Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a statistically significant improvement in progression-free survival (PFS) ...
Schneider Electric and JLL examine nine measures that could help healthcare organizations save money and reduce carbon dioxide emissions as they upgrade their infrastructure.
Prothena Corporation plc kept at Hold after mixed phase 2 results; key phase 3 readouts expected 2029. Click for this updated ...
Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD programPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #CELMoD--Bristol ...
Poplar Therapeutics is seeking a “step change” in the treatment of food allergy and other atopic conditions, with $95 million ...
Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by ...
With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.
The Cybernetics Association (UG) and Technophite Association (PG) of the School of IT of St Joseph’s University, Bengaluru hosted SYNTAXIA 2026, a vibrant National Inter-College Technical Fest, on ...
Jen Holifield has multiple myeloma, an incurable blood cancer. Her doctor prescribed Lenalidomide — brand name Revlimid — to treat it. She has not been able to fill that prescription in more than two ...
Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clinic ...
Although major pharmaceutical companies have fallen in line with President Donald Trump’s “most favored nation” (MFN) drug pricing agenda, the specifics of their negotiated concessions and the actu | ...
India’s manufacturing sector is expected to play a crucial role in driving economic growth, with the government targeting a ...